In fact, while Tyr acts on the β-catenin and TGF-β pathways in breast cancer [104], in the same cancer model OC modulates the HER2/MET pathway and reduces vimentin by significantly inhibiting the recurrence rate [70], which is what makes these compounds exploitable in post-surgery therapy. The gene discussed is MET; the disease is breast carcinoma.